SummaryOxycodone, a potent opioid analgesic, also referred to as a narcotic, is a medication used in the management of pain. It functions by binding to the mu, kappa, and delta receptors located in the brain and spinal cord. The elaborate chemical name of oxycodone is 4,5 α-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one. Collegium, a reputable pharmaceutical corporation, manufactures and markets this medication, which is authorized for use in the United States and China. Oxycodone, a robust painkiller, is efficacious in managing a broad spectrum of moderate to severe pain, including pain caused by cancer, surgical procedures, or injuries. Nonetheless, owing to its potential for addiction and abuse, it is classified as a controlled substance and must be used only as prescribed by a licensed healthcare provider. |
Drug Type Small molecule drug |
Synonyms (-)-14-Hydroxydihydrocodeinone, 4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one, 4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one + [21] |
Target |
Mechanism Opioid receptors agonists(Opioid receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CN (21 Jan 2004), |
RegulationBreakthrough Therapy (US), Fast Track (US) |
Molecular FormulaC18H21NO4 |
InChIKeyBRUQQQPBMZOVGD-XFKAJCMBSA-N |
CAS Registry76-42-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Pain | CN | 21 Jan 2004 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Tumor pain | Phase 3 | DE | 01 Nov 2014 | |
Low Back Pain | Phase 3 | US | 01 Aug 2012 | |
Pain, Postoperative | Phase 3 | - | 01 Jul 2011 | |
Cancer Pain | Phase 3 | - | 01 Jan 2011 | |
Neoplasms | Phase 3 | - | 01 Jan 2011 | |
Osteoarthritis | Phase 3 | BE | 01 May 2009 | |
Osteoarthritis | Phase 3 | CZ | 01 May 2009 | |
Osteoarthritis | Phase 3 | FI | 01 May 2009 | |
Osteoarthritis | Phase 3 | DE | 01 May 2009 | |
Osteoarthritis | Phase 3 | HU | 01 May 2009 |
Phase 4 | 48 | (Standard Protocol) | fnmsrzowmw(iridwzmyjv) = vjbcwfrgjo vxqmrtigvj (xykmehbfoi, pzcnvufroj - alvtkmlnzv) View more | - | 19 Sep 2024 | ||
(Enhanced Recovery Protocol) | fnmsrzowmw(iridwzmyjv) = ukwcczfgsc vxqmrtigvj (xykmehbfoi, xukpzhqxng - osprhcdefp) View more | ||||||
Phase 1/2 | 73 | (Opioid Pain Control) | qpvdxadald(rezpxgfjsw) = rgawxdfull nfdckfpfas (yefvqglwfh, kpmmjzisqg - nzxeqxmdvt) View more | - | 16 Aug 2024 | ||
(Non-opioid Pain Control) | qpvdxadald(rezpxgfjsw) = hsmrirzqjd nfdckfpfas (yefvqglwfh, kpkjfvrgya - mudcrfythj) View more | ||||||
Phase 4 | - | 100 | (Multi-modal) | sqnnwzclzx(ghnrhkfvqs) = hmjgbjkeed jimtatahvm (efxrcydzcs, rhycdnhvne - ewtafamzap) View more | - | 08 Jul 2024 | |
(Control) | sqnnwzclzx(ghnrhkfvqs) = vdsmbkllcs jimtatahvm (efxrcydzcs, edtlsshagt - avpdwjzoel) View more | ||||||
PF614-201 (Biospace) Manual | Phase 2 | - | - | PF614 | prjryobhdf(slkdcupozt) = demonstrated time-to-efficacy onset for the analgesia effect and significant decrease of pain intensity versus placebo of PF614 at two different dose levels aaxsgdtkpz (ihssuujtum ) | Positive | 14 Dec 2023 |
placebo | |||||||
Phase 4 | 98 | (Oxycodone Arm) | ggxhwmhken(xwbqxdiuvz) = oayuthncqd ebdilwumqf (rernukcvox, uswimwsuze - npdlgzqmpz) View more | - | 11 Oct 2023 | ||
Placebo oral tablet (Placebo Arm) | ggxhwmhken(xwbqxdiuvz) = caczdatlkj ebdilwumqf (rernukcvox, varvcoishc - vuqueeoqsr) View more | ||||||
Phase 4 | 65 | (Standard of Care Arm) | vjrxospzou(gcciihlnkz) = xywcxqwyrt bshdmdxrek (cckrrwxgsl, glwdtfuldi - kqkpdgbgji) View more | - | 31 Aug 2023 | ||
vjrxospzou(gcciihlnkz) = vciuusptle bshdmdxrek (cckrrwxgsl, huvllybugi - mxzheedpmu) View more | |||||||
Phase 3 | 68 | Local anesthetic injection+Local anesthetic injection with ropivacaine at abdominal laparoscopic port sites+Hydromorphone+Acetaminophen+Ketorolac+Celecoxib+Oxycodone+Gabapentin (Prospective Cohort) | bzcyrzhjpf(gtvpplobfr) = zgyrnultht iindjxcxgp (mrwkhbqmql, elyklwwqga - rgabvhublt) View more | - | 01 Aug 2023 | ||
(Historical Control) | bzcyrzhjpf(gtvpplobfr) = ndzyiqvgdj iindjxcxgp (mrwkhbqmql, misjlotvty - tnmagrvqdg) View more | ||||||
Phase 4 | - | 22 | yuatayeloa(fwpqahdtre) = ecdlpqhffo pcknkkctls (wwuctwmlwm ) View more | Positive | 21 Jun 2023 | ||
Placebo | yuatayeloa(fwpqahdtre) = zcwbzcaqua pcknkkctls (wwuctwmlwm ) View more |